Deubiquitinase inhibitors: Targeting SARS ‐ CoV ‐2 papain‐like protease with antiviral efficacy in a murine model
The FEBS Journal · 2026
DOI: 10.1111/febs.70399 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, 2026. Verfasst von Shweta Choudhary und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, India. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, COVID-19 Drug Treatment, Coronavirus Papain-Like Proteases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 115 Literaturangaben. Gefördert von: Science and Engineering Research Board.
Abstract (Originalsprache)
SARS‐CoV‐2 papain‐like protease (PLpro) is a key antiviral target as it plays a dual role in viral replication and modulation of innate immune responses by deubiquitinating or deISGylating host proteins. Therefore, therapeutically targeting PLpro may serve as a two‐pronged approach to mitigate SARS‐CoV‐2 infection. Interestingly, PLpro shares structural and functional similarities with cellular deubiquitinating enzymes (DUBs), and this fact was leveraged in our study to identify DUB inhibitors that target the ubiquitin/ISG15‐binding site and the known substrate‐binding pocket of PLpro. Among the identified compounds, flupenthixol, lithocholic acid, teneligliptin, and linagliptin markedly inhibited the proteolytic activity of purified PLpro and demonstrated potent antiviral effects against SARS‐CoV‐2 infection in a dose‐dependent manner. Treatment with lithocholic acid and linagliptin suppressed the expression of inflammatory mediators, thereby restoring immune responses. Here, crystal structures of SARS‐CoV‐2 PLpro in complex with linagliptin and with lithocholic acid were determined, revealing insights into the mechanism of inhibition and unique interactions within the ubiquitin/ISG15‐binding site (S2 site; Phe69, His73, Asn128, and His175) and the substrate‐binding cleft. Additionally, oral and intraperitoneal treatments with linagliptin increased survival, reduced lung viral load, and ameliorated histopathological damage in a mouse‐adapted model of SARS‐CoV‐2 infection. This study demonstrates for the first time that using DUB inhibitors that target the proteolytic activity of PLpro can simultaneously reinstate the host's immune response against SARS‐CoV‐2, highlighting the potential of this two‐pronged therapeutic approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, India.
- Centre for Infectious Disease Research, Microbiology & Cell Biology Department, Bangalore, India.
- Shiv Nadar University, Uttar Pradesh, India.
- Indian Veterinary Research Institute, Bareilly, India.
ORCID-Profile: Gaurav Kumar Sharma, Pravindra Kumar, Shailly Tomar
Förderung
- Science and Engineering Research Board
Zitieren
APA
Choudhary, S., Nehul, S., Nagaraj, S. K., Narayan, R., Verma, S., Sharma, S., Kumari, A., Rani, R., Saha, A., Sircar, D., Kaliappan, A., Tripathi, S., Sharma, G. K., Kumar, P., & Tomar, S. (2026). Deubiquitinase inhibitors: Targeting SARS ‐ CoV ‐2 papain‐like protease with antiviral efficacy in a murine model. The FEBS Journal. https://doi.org/10.1111/febs.70399
Vancouver
Choudhary S, Nehul S, Nagaraj SK, Narayan R, Verma S, Sharma S, et al. Deubiquitinase inhibitors: Targeting SARS ‐ CoV ‐2 papain‐like protease with antiviral efficacy in a murine model. The FEBS Journal. 2026. doi:10.1111/febs.70399
BibTeX
@article{Choudhary2026,
author = {Choudhary, Shweta and Nehul, Sanketkumar and Nagaraj, Santhosh Kambaiah and Narayan, Rohan and Verma, Shalja and Sharma, Swati and Kumari, Annu and Rani, Ruchi and Saha, Ankita and Sircar, Debabrata and Kaliappan, Abinaya and Tripathi, Shashank and Sharma, Gaurav Kumar and Kumar, Pravindra and Tomar, Shailly},
title = {Deubiquitinase inhibitors: Targeting SARS ‐ CoV ‐2 papain‐like protease with antiviral efficacy in a murine model},
journal = {The FEBS Journal},
year = {2026},
doi = {10.1111/febs.70399}
}
EUVIMED